v3.26.1
Segment Information - Schedule of Segment Information about Segments Net Loss (Details) - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2026
Mar. 31, 2026
Jun. 30, 2025
Mar. 31, 2025
Jun. 30, 2026
Jun. 30, 2025
Segment Reporting, Descriptive Information [Abstract]            
Collaboration revenue $ 0   $ 959   $ 0 $ 2,877
Research and development expenses associated with preclinical and clinical studies [1] 22,941   16,178   42,548 33,213
Facilities and related expenses, excluding depreciation and amortization [2] 2,838   2,407   5,460 11,287
General and corporate expenses [3] 3,658   7,552   6,393 10,277
Personnel-related expenses, excluding stock-based compensation 10,538   12,368   21,487 26,175
Other segment items [4] 12,813   3,689   15,162 1,595
Segment net loss $ 52,788 $ 38,262 $ 41,235 $ 38,435 $ 91,050 $ 79,670
[1] Research and development expenses associated with preclinical and clinical studies includes research software, professional services and laboratory operations supporting the Company’s research and development programs.
[2] Facilities and related expenses includes rent, common area maintenance costs, repairs and maintenance, utilities and real estate taxes.
[3] General and corporate expenses include general and administrative costs associated with professional and consulting fees and other overhead costs.
[4] For the three and six months ended June 30, 2026 and 2025, other segment items consist of interest income, stock-based compensation expense, depreciation and amortization expense, change in fair value of contingent consideration expense, income tax (benefit) provision and other (income) expense, net. Interest income consists of interest income earned on cash equivalents and marketable securities. Interest expense consists of interest expense on finance leases. Other (income) expense, net primarily consists of realized and unrealized gains and losses on marketable securities.